The estimated Net Worth of Melissa Price is at least $1.65 Thousand dollars as of 5 June 2014. Melissa Price owns over 692 units of Heat Biologics Inc stock worth over $1,647 and over the last 10 years Melissa sold HTBX stock worth over $0.
Melissa has made over 1 trades of the Heat Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Melissa bought 692 units of HTBX stock worth $2,976 on 5 June 2014.
The largest trade Melissa's ever made was buying 692 units of Heat Biologics Inc stock on 5 June 2014 worth over $2,976. On average, Melissa trades about 231 units every 0 days since 2014. As of 5 June 2014 Melissa still owns at least 692 units of Heat Biologics Inc stock.
You can see the complete history of Melissa Price stock trades at the bottom of the page.
Melissa's mailing address filed with the SEC is C/O 801 CAPITOLA DRIVE, , DURHAM, NC, 27713.
Over the last 11 years, insiders at Heat Biologics Inc have traded over $311,853 worth of Heat Biologics Inc stock and bought 1,805,692 units worth $1,373,576 . The most active insiders traders include Louis C Bock, Michael Kharitonov, and John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of $582,988. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth $205,450.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Heat Biologics Inc executives and other stock owners filed with the SEC include: